Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that company executives will be presenting at LD Micro’s elite LD 500 Virtual Investor Conference. The presentation is scheduled for Wednesday, Sept. 2, 2020, at 3:40 p.m. ET. An archived copy of the webcast … Continue reading “NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Slated for Presentation at Prestigious LD 500 Virtual Investor Conference”
Predictive Oncology (NASDAQ: POAI), together with its TumorGenesis subsidiary, has achieved significant breakthroughs in applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. Earlier in June, TumorGenesis, which is developing a new rapid approach to growing tumors in the laboratory, sold its first order of unique ovarian cancer cell culture media to … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) and TumorGenesis Advancing Path Toward Patient-Specific Treatments”
POAI, Helomics builds AI-driven models that predict drug response, patient outcome Company tests patient tumor, generates comprehensive picture that oncologists use to individualize therapy Key to individualized insight is POAI’s Tumor Drug Response Profiling (“TDRP”) platform, NGS-based genomic profiling, unmatched cancer knowledge base Guided by the mantra that “cancer is personal — we believe therapy … Continue reading “Predictive Oncology Inc.’s (NASDAQ: POAI) Exclusive Resources Provide Personal Profiling, Tools to Improve Patient Outcomes”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that its Soluble Biotech division has finalized its first major contract since being acquired by POAI earlier this year. The contract calls for a project involving protein expression followed by solubility studies, both areas of … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Lands Milestone Contract with Major Pharmaceutical Company”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its Skyline Medical division, producer of the FDA-approved and CE-marked STREAMWAY(R) System for automated, direct-to-drain medical fluid disposal, has completed the sale of eight systems to a large university hospital organization in Virginia … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Sale of 8 Skyline Medical STREAMWAY(R) Systems to Large University Hospital Organization”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, on Thursday released financial results for the quarter ended June 30, 2020 and provided a business update. “During the second quarter we reached a major milestone in our journey towards full commercialization with the first sale … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Q2 2020 Results, Business Update and DojoLIVE! Interview”
Appointments signify POAI’s commitment to aligning board’s expertise with company’s strategic vision Board members to support development, commercialization of unique offering that improves outcomes for oncology patients, value to shareholders New appointments effective immediately Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine, announced the appointment of three … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Appoints New Board Members; Adds Depth of Knowledge, Experience to Strengthen Company’s Vision”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, outlined the company’s recent accomplishments in a letter released to shareholders. The letter, sent from CEO Dr. Carl Schwartz, also summarized voting recommendations from POAI’s Board of Directors regarding two proposals that are scheduled for shareholder … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Shareholder Letter Highlights Achievements, Discusses Two Key Proposals”
Predictive Oncology (NASDAQ: POAI), through its subsidiary TumorGenesis and working with distributor US Biological Corporation, has accomplished a major achievement. Recently, the company announced its first-ever commercial order of a novel ovarian cancer cell culture media for cancer cells collected from patient-derived samples (“PDx”) (http://nnw.fm/zLCh3). An article discussing this quotes Richard Gabriel of TumorGenesis, who … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Marks Milestone in Applying AI to Find New Targets for Treatment, Diagnostics”
TumorGenesis president Richard Gabriel selected to feature as keynote presenter at inaugural Drug Discovery & Preclinical Virtual Summit The summit features over 150 delegates from across bio-pharmaceutical industry coming together to market sector’s latest breakthroughs TumorGenesis, which specializes in creating laboratory-grown cancer cells directed towards ovarian cancer research, recently announced its first sale of cancer … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI)’s TumorGenesis Presents at Precision in Drug Discovery & Preclinical Virtual Summit”
